BioHarvest Sciences (NASDAQ:BHST) Shares Down 0.7% – Here’s Why

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) fell 0.7% on Thursday . The stock traded as low as $2.76 and last traded at $2.83. 52,994 shares changed hands during trading, an increase of 79% from the average daily volume of 29,619 shares. The stock had previously closed at $2.85.

Analysts Set New Price Targets

Separately, Weiss Ratings raised BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

BioHarvest Sciences Stock Down 4.6%

The company has a market capitalization of $52.97 million, a PE ratio of -4.58 and a beta of 0.87. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.44 and a current ratio of 2.96. The stock’s 50 day moving average is $3.30 and its 200 day moving average is $4.15.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The company had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.50 million. On average, sell-side analysts anticipate that BioHarvest Sciences Inc. will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On BioHarvest Sciences

Several hedge funds have recently made changes to their positions in the stock. True North Advisors LLC raised its stake in shares of BioHarvest Sciences by 381.0% during the 1st quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock valued at $729,000 after purchasing an additional 133,085 shares during the period. Silverberg Bernstein Capital Management LLC bought a new position in BioHarvest Sciences in the 1st quarter worth about $113,000. Virtu Financial LLC bought a new position in BioHarvest Sciences in the 4th quarter worth about $60,000. XTX Topco Ltd purchased a new position in BioHarvest Sciences during the 4th quarter valued at about $173,000. Finally, Quadrature Capital Ltd purchased a new position in BioHarvest Sciences during the 4th quarter valued at about $140,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.